On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

January 31, 2025

By Al-Ola Abdallah, MD
Muhammad Umair Mushtaq, MD

Opinion

Video

Panelists discuss how expanding CAR T therapy into earlier lines of multiple myeloma treatment requires careful evaluation of clinical trial data, infrastructure readiness, patient selection criteria, and manufacturing capacity while balancing the therapy’s potential benefits against established treatment approaches.

EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process

EP: 5.Reviewing CAR T Mechanism & Treatment Process

EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process

EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T

Now Viewing

EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?

EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

Video content above is prompted by the following:

Looking ahead, what are your institution’s plans or considerations for further expanding the role of CAR T therapy in earlier lines of multiple myeloma treatment?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!